Trial · NCT02515630
Outcomes25
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Transfusion Independence Response by Week 24 | From baseline to Week 24 | Assessed in the Safety Analysis Set, which includes all subjects who received ≥ 1 dose of momelotinib. Note that 6 subjects discontinued prior to Week 12 and could not be evaluated over the minimum period required for assessment of the endpoint (12 weeks). | percentage of subjects | NUMBER |
| SECONDARY | Transfusion Response Rate by Week 24 | From baseline to Week 24 | Assessed in the Safety Analysis Set, which includes all subjects who received ≥ 1 dose of momelotinib. Note that 3 subjects discontinued prior to Week 8 and could not be evaluated over the minimum period required for assessment of the endpoint (8 weeks). | percentage of subjects | NUMBER |
| SECONDARY | Splenic Response Rate at Week 24 | Measured at Week 24 | Assessed in the Safety Analysis Set, which includes all subjects who received ≥ 1 dose of momelotinib. Note that spleen volume at Week 24 was not available for 15 subjects. | percentage of subjects | NUMBER |
| SECONDARY | Response Rate in Total Symptom Score (TSS) at Week 24 | Measured at Week 24 | There were 3 subjects with missing TSS at baseline who were excluded from the analysis. Note that of the 38 subjects evaluated, 17 were missing Week 24 TSS assessments. | percentage of subjects | NUMBER |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Change From Baseline in Hepcidin Daily Change | At baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20 and 24 | nM | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Trough Hepcidin | At baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20 and 24 | nM | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Serum Iron | At Weeks 2, 4, 8, 12, 16, 20 and 24 | % Change from baseline | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Hemoglobin | At Weeks 2, 4, 8, 12, 16, 20 and 24 | % Change in from baseline | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Total Iron Binding Capacity | At Weeks 2, 4, 8, 12, 16, 20 and 24 | % Change from baseline | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Reticulocytes | At Weeks 2, 4, 8, 12, 16, 20 and 24 | % Change from baseline | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Reticulocytes/Erythrocytes% | At Weeks 2, 4, 8, 12, 16, 20 and 24 | % Change from baseline | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Erythropoietin | At Weeks 8 and 20 | % Change from baseline | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Erythrocytes | At Weeks 2, 4, 8, 12, 16, 20 and 24 | % Change from baseline | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Hematocrit | At Weeks 2, 4, 8, 12, 16, 20 and 24 | % Change from baseline | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Ferritin | At Weeks 2, 4, 8, 12, 16, 20 and 24 | % Change from baseline | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Soluble Transferrin Receptor | At Weeks 2, 4, 8, 12, 16, 20 and 24 | % Change from baseline | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Transferrin Saturation | At Weeks 2, 4, 8, 12, 16, 20 and 24 | % Change from baseline | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Unsaturated Iron Binding Capacity | At Weeks 2, 4, 8, 12, 16, 20 and 24 | % Change from baseline | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Platelets | At Weeks 2, 4, 8, 12, 16, 20 and 24 | % Change from baseline | MEDIAN | |
| SECONDARY | Change in Markers of Iron Metabolism and Anemia - Leukocytes | At Weeks 2, 4, 8, 12, 16, 20 and 24 | % Change from baseline | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02515630/outcomes